Pricing updated 2019-07-17. Prices are subject to change without notice.
Lanifibranor is an agonist of peroxisome proliferator-activated receptors (PPARs) with EC50 values of 1,537, 866, and 206 nM for human recombinant PPARα, PPARβ, and PPARγ, respectively, for transactivation activity.1 It increases β-oxidation in Huh-7 and C2C12 cells when used at concentrations of 1 and 3 µM, respectively, and increases the expression of the PPARγ target genes adipocyte protein 2 (aP2) and adiponectin in adipocytes. Lanifibranor reduces plasma glucose and triglyceride levels in a db/db mouse model of type 2 diabetes when administered at doses of 10 and 30 mg/kg for five days. It also increases plasma adiponectin levels and decreases collagen deposition in a carbon tetrachloride-induced mouse model of non-alcoholic steatohepatitis (NASH).
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
1. Boubia, B., Poupardin, O., Barth, M., et al. Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) α/γ/δ triple activators: Discovery of lanifibranor, a new antifibrotic clinical candidate J. Med. Chem. 61(6), 2246-2265 (2018).